Advantages of using thalidomide for the management of refractory myeloma patients.
A group of 11 heavily pretreated patients receiving low-dose thalidomide was compared with a similar group of 10 patients with refractory myeloma treated with a convention-al oral chemotherapy. This study shows that thalidomide is not only effective in controlling the neoplastic clone but more-over, thanks to its low toxicity, allows out-patient management of these subjects.
Corso
Alessandro
A
Lorenzi
Angela
A
Orlandi
Ester
E
Astori
Cesare
C
Mangiacavalli
Silvia
S
Lazzarino
Mario
M
D000368:Aged; D000553:Ambulatory Care; D019468:Disease Management; D004341:Drug Evaluation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000633:toxicity; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012189:Retrospective Studies; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage* / Q000633:toxicity
D007166:Immunosuppressive Agents; D013792:Thalidomide